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Objectives: Despite relevant treatments, only 29% of type 2 diabetes (T2DM) 
patients in Greece achieve their pre-defined glycemic targets. When treatment 
with metformin (MF) fails to control T2DM patients, add-on therapies are needed. 
Sitagliptin is indicated as second-line therapy in Greece, after treatment with MF 
has failed and is a valid option in the proposed national therapeutic protocols. 
The present study aimed to assess the cost-effectiveness of adding Sitagliptin to 
MF vs adding sulphonylurea (SU) to MF for the treatment of T2DM patients with 
inadequate glycemic control. MethOds: A published individual-level simulation 
model was developed to simulate the lifetime medical cost, diabetic complications, 
drug-related adverse events, life expectancy and quality adjusted life years (QALYs) 
associated with Sitagliptin add-on therapy versus SU add-on therapy. The model is 
developed based upon the UKPDS 68 risk equations to project long-term complica-
tions and mortalities. Efficacy and safety profiles of drugs were obtained from a 
head-to-head trial. Costs (€ 2014 prices) and effects were discounted at 3.5% annu-
ally. Greek data retrieved by an expert input forum of specialists. Sensitivity analyses 
performed on 17 parameters. Analysis based on Greek payer perspective. Results: 
Sitagliptin strategy is projected to cost 359 EUR more than SU strategy per patient 
over lifetime. Sitagliptin showed reductions in diabetes-related complications and 
adverse events. The incremental QALY for Sitagliptin strategy is 0.042, primarily 
driven by the improved outcomes associated with hypoglycemia, body weight 
change, and MI. The incremental cost effectiveness ratio (ICER) is 8,582 € /QALY 
gained. Sensitivity analysis conducted varied multiple parameters. ICER ranges 
from 4,873 to 12,173 € /QALY gained. The results are robust and never exceeded the 
30,000€ /QALY threshold. cOnclusiOns: Sitagliptin add-on strategy could be cost-
effective, compared to SU, for the Greek healthcare setting. Furthermore, it remains 
cost-effective in all types of sensitivity analysis.
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Objectives: to assess the cost effectiveness of saxagliptin (SAXA) vs sitagliptin 
(SITA) or vildagliptin (VILDA) as add-on therapy to metformin (MET) in patients with 
type 2 diabetes mellitus (T2DM) and inadequate glycaemic control on metformin 
alone. MethOds: the Cardiff Diabetes Model was adapted to the Russian health-
care setting. We modeling events, efficacy, total costs for managing patients with 
T2DM: 1-st line – monotherapy metformin alone, 2-nd line (target groups) – SAXA or 
SITA or VILDA plus metformin, 3-nd line – insulin rescue therapy. The model simu-
lated the disease progression and treatment effects for 40 years (8-26-6 years for 
1-2-3 lines respectively). The effectiveness measure was quality-adjusted life years 
(QALYs) gained per patient. Results: in case short-time efficacy (decrease HBA1c 
-1%) cost-effectiveness ratio (CER) for SAXA+MET was the lowest: $835 per QALY. 
When compared with SITA+MET for the long-term efficacy (40 years), SAXA+MET 
was the dominant strategy, i.e. less costly (-$505) and more effective (+0.16 QALY). 
When compared to VILDA+MET, SAXA+MET was more costly (+$364), but more 
effective (+0.14 QALY). The incremental cost-effectiveness ratio (ICER) per responder 
for SAXA+MET vs VILDA+MET was estimated at $2,566 per QALY gained and would 
be cost effective at the willingness-to-pay (WTP) threshold $36,373/QALY for 
Russia in 2014. If we used combined medicines: Kombiglyce (SAXA+MET), Janumet 
(SITA+MET) and Galvus Met (VILDA+MET), then Kombiglyce interventions were also 
more efficacious than Janumet and Galvus Met, but were associated with increased 
total costs. The ICERs per responder for Kombiglyce were estimated at $3,216/QALY 
(vs Janumet), $3,269/QALY (vs Galvus Met) and would be cost effective at the WTP 
threshold $36,373/QALY for Russia in 2014. cOnclusiOns: at a willingness-to-pay 
threshold of $36,373/QALY SAXA+MET and Kombiglyce is likely to be a cost-effective 
option for the treatment of T2DM in adult patients in Russia.
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Objectives: Establish incremental cost-effectiveness ratio (ICER) in cost per 
additional patient with glycemic control for all the oral antidiabetic medications 
available in Colombia, as a second-line treatment for adult patients with type 2 
diabetes (DM2), who do not reach therapeutic targets with metformin and are 
not yet considered candidates for insulin therapy. MethOds: Oral antidiabetic 
medications were divided into drug classes: sulfonylureas (divided between glib-
enclamide, other sulphonylureas), thiazolidinediones, GLP-1 receptor agonists, and 
DPP4 inhibitors. A systematic review of the literature was done to obtain transition 
probabilities in a Markov model (monthly cycles, time horizon one year) designed 
to represent the Colombian health system perspective. The main outcome consid-
ered was glycemic control, but data on adherence and adverse events were also 
collected. Costs (in 2014 Colombian pesos; 1 euro = COP 2,660) were estimated 
from base cases obtained from multidisciplinary expert panel meetings, with 
local costs applied from national tariff manuals and official drug price registries. 
Sensitivity analyses were performed. Results: Annual treatment costs ranged 
from € 116 for glibenclamide, and € 98 for other sulphonylureas, to € 12,205 for 
GLP-1 receptor agonists. Number of patients with glycemic control (per 1000) were 
glibenclamide 145, sulphonylureas 265, thiazolidinediones 472, GLP-1 receptor 
agonists 326, and DPP4 inhibitors 417: Compared against other sulfonylureas, 
glibenclamide was dominated, while ICERs per additional patient with glycemic 
control per year would be € 516 for DPP-4 inhibitors, € 712 for thiazolidinediones 
and € 66,790 for GLP-1 receptor agonists. Critical variables in the sensitivity analy-
ses were drug costs (particularly for GLP-1 receptor agonists), but also patient 
policy making. MethOds: A published decision-analysis tool (the GeDiForCETM) 
was employed to assess cost-effectiveness of GDM screening by comparing costs 
and averted disability-adjusted life years (DALYs) with no GDM screening. As mod-
eling inputs, costs for GDM screening and antenatal care, incidence and cost of 
GDM perinatal adverse effects (PAE) were based on an investigation on 6 tertiary 
hospitals from different cities in China as part of this analysis. Cost for postpartum 
care was calculated based on literature and adjusted for China. PAE-DALYs, life-
time cost for postpartum T2DM, and effectiveness of interventions were collected 
from literature. Annual discount rate was 3.0%. One-way sensitivity analyses were 
conducted on some key indicators. Results: The total costs of GDM screening, 
intervention and life-time treatment per 1000 pregnant women were $7,092,398 in 
GDM screening group, saving $1,329,671 comparing with no screening. 277.4 DALYs 
were averted in screening group, which was mainly brought out by GDM postpartum 
care for T2DM prevention. Sensitivity analyses demonstrated robustness of the 
results. cOnclusiOns: GDM screening and interventions are cost-saving in an 
urban Chinese setting by IADPSG standards. As DALYs averted mainly comes from 
T2DM prevention, China should pay more attention to providing postpartum care 
for GDM women in the future.
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Objectives: Improving glycaemic control is the primary goal of T2DM manage-
ment and can help to reduce the risk of micro- and macrovascular complications. 
Guidelines from the American Diabetes Association and European Association for 
the Study of Diabetes recommend lowering HbA1c to levels < 7.0% for most patients. 
This analysis compared the cost of reaching this target (HbA1c < 7.0%) using cana-
gliflozin versus dapagliflozin, two compounds that inhibit sodium glucose co-trans-
porter 2 (SGLT2), in dual therapy as add-on to metformin from the payer perspective 
in the UAE. MethOds: A Bayesian network meta-analysis (NMA) was conducted 
to compare the efficacy of canagliflozin 100 and 300 mg versus dapagliflozin 10 
mg in terms of the percentage of patients that achieved the HbA1c goal of < 7.0% 
at 26 weeks. Based on the NMA results and the acquisition cost of dapagliflozin 
in the UAE ($1.77 per day), we calculated what the daily acquisition cost of each 
dose of canagliflozin would be if the costs of a patient reaching the target with 
canagliflozin 100 and 300 mg were equalized to the cost of reaching the target with 
dapagliflozin 10 mg. Results: In dual therapy as add-on to metformin, patients 
using canagliflozin 100 and 300 mg were more likely to achieve HbA1c < 7.0% com-
pared to those using dapagliflozin 10 mg, with odds ratios of 1.3 (Pr= 82%) and 1.7 
(Pr= 96%), respectively. The costs of canagliflozin 100 and 300 mg that equalized the 
cost of reaching HbA1c < 7.0% with dapagliflozin 10 mg were $2.11 and $2.45 per 
day, respectively. cOnclusiOns: These results suggest that adding canagliflozin 
100 or 300 mg instead of dapagliflozin 10 mg in patients inadequately controlled 
on metformin would result in a more efficient use of resources with costs per day 
up to these break-even levels.
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Objectives: This study was designed to assess the cost-effectiveness of vildagliptin 
versus glimepiride as add-on to metformin in the management of type 2 diabetes 
mellitus (T2DM) patients in the Greek healthcare setting. MethOds: A cost-effec-
tiveness model was designed, using MS Excel, to compare two treatment strategies. 
Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in 
second-line, and metformin + basal insulin and metformin + basal + rapid insulin 
in subsequent lines. Strategy 2 differed from strategy 1 only in second-line, where 
metformin was administered with glimepiride. Clinical data and utilities were taken 
from the published literature. Only direct medical costs were included in the analy-
sis (cost base year 2014), and consisted of drug, side-effect and comorbidity costs 
(taken from local officially published sources and the literature). The perspective 
adopted was that of the Social Insurance Fund. The time horizon was lifetime, and 
costs and outcomes were discounted at 3.5%. Results: Adding vildagliptin to met-
formin increased drug costs compared with adding glimepiride to metformin (€ 2,853 
vs. € 2,427, respectively). However, this increase was completely offset by a decrease 
in the costs of associated comorbidities (€ 4,393 vs. € 4,539) and side-effects (€ 3,015 vs. 
€ 3,510), resulting in a lower total cost of € 214.6 in strategy 1 compared with strategy 
2. Comorbidities were the largest cost component in both strategies, accounting for 
42.8% and 43.3% in strategies 1 and 2, respectively. Strategy 1 was also associated 
with increased life-years (LYs, 0.11) and quality-adjusted life-years (QALYs, 0.11) 
compared with strategy 2. Strategy 1 is therefore dominant, as it is associated with 
both lower overall costs and increased effectiveness. cOnclusiOns: Vildagliptin as 
add-on treatment to metformin in the management of T2DM in Greece appears to 
be dominant vs. glimepiride in terms of both cost per LY and cost per QALY gained.
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